Lexeo Therapeutics, (US:LXEO) — Company Overview, News & Financial Data

Lexeo Therapeutics, logo
LXEOLexeo Therapeutics,
Trade LXEO now
Lexeo Therapeutics, primary media

About Lexeo Therapeutics,

Lexeo Therapeutics (NASDAQ:LXEO) is a biotechnology firm focused on developing genetic medicines for life-altering disorders. Their portfolio spans a range of projects aimed at tackling cardiovascular, neurodegenerative, and rare diseases. By leveraging cutting-edge gene therapy technologies, Lexeo Therapeutics strives to bring innovative treatments from the lab to patients in need. Their objectives center on advancing their clinical pipeline, prioritizing safety and efficacy, and ultimately improving patient outcomes. Their commitment to research and development is driven by a deep understanding of genetic medicine's potential to offer transformative therapies.

What is LXEO known for?

Snapshot

Public US
Ownership
2017
Year founded
58
Employees
New York, United States
Head office
Loading Map...

Operations

All Locations
New York City, US

Products and/or services of Lexeo Therapeutics,

  • Gene therapy for Friedreich’s Ataxia, focusing on correcting the genetic defect causing this neurodegenerative disease.
  • A gene therapy approach targeting APOE4-related Alzheimer’s disease, aiming to address genetic risk factors.
  • Development of therapies for genetic forms of cardiomyopathy, aiming to address heart muscle disorders.
  • Innovative treatments for Parkinson’s disease, focusing on genetic contributors to improve disease management.
  • Gene editing technologies targeting rare genetic disorders, offering potential cures or substantial improvements.
  • Advanced drug delivery systems enhancing the efficacy and safety of gene therapies.

Lexeo Therapeutics, executive team

  • Mr. R. Nolan Townsend M.B.A.CEO & Director
  • Dr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Mr. Louis TamayoCFO & Principal Accounting Officer
  • Ms. Jenny R. Robertson J.D.Chief Legal Officer
  • Mr. Jordan M. Baumhardt Ph.D.Vice President of Corporate Development
  • Dr. Sandi See Tai M.D.Chief Development Officer
  • Ms. Leslie DiRisioSenior Vice President of Development Operations

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.